Interviews

Bispecific antibodies, CAR T therapy, and targeted drugs transform non-Hodgkin lymphoma care, with earlier use and MRD-guided strategies poised to boost outcomes.

Theodore Wagener, PhD, of Ohio State discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.

Theodore Wagener, PhD, discusses psychedelics beyond depression in cancer, including neuropathy and chemo brain, and why he expects cancer centers to adopt them.

Theodore Wagener, PhD, discusses an Ohio State feasibility study testing psilocybin-assisted therapy for depression in patients with non–small cell lung cancer.

Allogeneic and in vivo CAR T therapies simplify manufacturing and delivery, potentially expanding access to cellular therapy beyond specialized centers.

Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.

Amer M. Zeidan, MBBS, MHS, on how genetics, comorbidities, and goals of care guide acute myeloid leukemia treatment selection in real-world practice.

CLL care shifts to targeted combinations, confronting BTK resistance with next-gen inhibitors, degraders, and BCL2 drugs, while CAR T and pivotal trials reshape strategy.

Lyudmila Bazhenova, MD, explains why the updated taletrectinib label does not change her practice and reviews new WCLC subgroup data in ROS1+ NSCLC.

Paula Rodriguez-Otero, MD, discusses findings from the LINKER-SMM1 trial presented at the IMS Annual Meeting.

Eytan M. Stein, MD, explains how real-world data complements AML trials and where targeted agent combinations and immunotherapy research must go next.

Komal Jhaveri, MD, discusses the FDA approval of imlunestrant plus abemaciclib for ESR1-mutated breast cancer, EMBER-3 data, and what's next.

Sarah Premji, MD, of Sarah Cannon Research Institute, discusses community trial access, biomarker-driven drug development, and key breast cancer studies to watch.

Luciano Costa, MD, PhD, explains the findings from a competing risk analysis of the MajesTEC-3 trial linking survival to reduced myeloma progression.

Daniel Heng, MD, discusses the FDA approval of belzutifan plus lenvatinib in RCC, managing hypoxia and anemia, and how it may affect treatment sequencing.

Komal L. Jhaveri, MD, discusses the unmet need, EMBER-3 data, and future directions after the FDA approved imlunestrant plus abemaciclib for ESR1-mutated breast cancer.

Jorge Nieva, MD, discusses how long-term responses in ROS1+ non–small cell lung cancer affect imaging frequency, MRD testing, and treatment intensification.

Andrew T. Kuykendall, MD, explains the significance of the FDA approval of rusfertide for polycythemia vera.

Jorge Nieva, MD, reviews long-term taletrectinib data in ROS1+ non–small cell lung cancer, including about 90% response rates across fusion partners and manageable safety.

Telehealth transplant consults help patients with multiple myeloma overcome racial, age, and rural barriers, speeding eligibility screening and expanding access to specialists.

Andrew Kuykendall, MD, discusses where rusfertide may fit in polycythemia vera, from replacing phlebotomy to use with cytoreductive therapy and fatigue.

Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.

Daniel DeAngelo, MD, PhD, discusses how TKIs have given patients with CML a full lifespan and what is being done to build on the incredible progress in this setting.

Giada Bianchi, MD, discusses tailoring therapy in myeloma, addressing ultra-high-risk disease, and amyloidosis becoming a chronic condition at IMS 2026.

Andrew Kuykendall, MD, reviews VERIFY trial that led to FDA approval of rusfertide in polycythemia vera.

Saad Usmani, MD, discusses how MRD negativity may define treatment duration and raise cure fractions in multiple myeloma, live from IMS.

Daniel DeAngelo, MD, PhD, discusses how the field of AML is moving away from traditional chemotherapy and toward targeted triplet therapies.

At the 2026 IMS meeting, Sagar Lonial, MD, discusses the FDA approval of iberdomide, early enthusiasm for its use, and the CELMoD trials clinicians should watch.

Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.

As Leukemia and Lymphoma Awareness Month draws to a close, Daniel DeAngelo, MD, PhD, discusses the key trends in acute lymphoblastic leukemia treatment.